路易体痴呆与额颞叶变性的分子与解剖影像
本文综述路易体痴呆(DLB)与额颞叶变性(FTLD)的分子和解剖影像。DLB可用123I-FP-CIT SPECT、123I-MIBG及18F-FDG-PET辅助鉴别AD;FTLD以结构MRI评估萎缩模式,18F-FDG-PET有助鉴别。两者异质性大,结构联合功能影像可提高诊断准确性。
要点
- 123I-FP-CIT SPECT与123I-MIBG在鉴别DLB与AD中已有确立作用。
- 18F-FDG-PET可高准确度区分DLB与AD,并支持DLB诊断。
- FTLD结构影像示额颞叶萎缩,18F-FDG-PET低代谢灶常先于萎缩。
核心结论
- 结构影像与功能影像联合应用可提高DLB和FTLD的诊断准确性。
- 目前尚无生物标志物能明确诊断DLB或FTLD,两者均表现广泛异质性。
研究设计与样本
- 本文为综述,围绕DLB与FTLD的分子和解剖影像进行总结。
- 文中提及DLB影像涉及123I-FP-CIT SPECT、123I-MIBG与18F-FDG-PET,FTLD以结构MRI和18F-FDG-PET为主。
主要发现
- DLB与AD临床和影像重叠,结构联合功能影像有助鉴别。
- 与DLB相比,AD以内侧颞叶结构萎缩更明显,可用内侧颞叶萎缩量表在MR上评估。
- FTLD典型表现为额叶和颞叶萎缩,萎缩模式与临床亚型、潜在神经病理和基因突变相关但存在显著重叠。
- 18F-FDG-PET局灶性低代谢区常先于结构MRI所见的萎缩。
关键数值与推荐
- 123I-FP-CIT SPECT与123I-MIBG在区分DLB与AD中已有确立作用。
- 18F-FDG-PET作为DLB诊断的支持性生物标志物,可高准确度区分DLB与AD。
- 多导睡眠图和脑电图在DLB诊断中也有确立作用。
- 内侧颞叶萎缩量表用于MR评估内侧颞叶结构萎缩。
- 全局皮层萎缩量表用于MR评估FTLD的区域萎缩模式。
临床怎么用
- 对疑诊DLB者,可结合123I-FP-CIT SPECT、123I-MIBG与18F-FDG-PET辅助与AD鉴别。
- 对疑诊FTLD者,首选结构MRI评估额颞叶萎缩模式,必要时加做18F-FDG-PET。
- 诊断时应认识DLB与FTLD的异质性,采用结构联合功能影像的综合策略。
局限性
- 目前尚无生物标志物能明确诊断DLB或FTLD。
- DLB与FTLD均表现广泛异质性,且影像模式存在显著重叠。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dementia with Lewy bodies (DLB) and frontotemporal lobar degeneration (FTLD) are common causes of dementia. Early diagnosis of both conditions is challenging due to clinical and radiological overlap with other forms of dementia, particularly Alzheimer's disease (AD). Structural and functional imaging combined can aid differential diagnosis and help to discriminate DLB or FTLD from other forms of dementia. Imaging of DLB involves the use of 123I-FP-CIT SPECT and 123I-metaiodobenzylguanidine (123I-MIBG), both of which have an established role distinguishing DLB from AD. AD is also characterised by more pronounced atrophy of the medial temporal lobe structures when compared to DLB and these can be assessed at MR using the Medial Temporal Atrophy Scale. 18F-FDG-PET is used as a supportive biomarker for the diagnoses of DLB and can distinguish DLB from AD with high accuracy. Polysomnography and electroencephalography also have established roles in the diagnoses of DLB. FTLD is a heterogenous group of neurodegenerative disorders characterised pathologically by abnormally aggregated proteins. Clinical subtypes include behavioral variant FTD (bvFTD), primary progressive aphasia (PPA), which can be subdivided into semantic variant PPA (svPPA) or nonfluent agrammatic PPA (nfaPPA) and FTD associated with motor neuron disease (FTD-MND). Structural imaging is often the first step in making an image supported diagnoses of FTLD. Regional patterns of atrophy can be assessed on MR and graded according to the global cortical atrophy scale. FTLD is typically associated with atrophy of the frontal and temporal lobes. The patterns of atrophy are associated with the specific clinical subtypes, underlying neuropathology and genetic mutations although there is significant overlap. 18F-FDG-PET is useful for distinguishing FTLD from other forms of dementia and focal areas of hypometabolism can often precede atrophy identified on structural MR imaging. There are currently no biomarkers with which to unambiguously diagnose DLB or FTLD and both conditions demonstrate a wide range of heterogeneity. A combined approach of structural and functional imaging improves diagnostic accuracy in both conditions.
引用
- Duignan JA, Haughey A, Kinsella JA, et al. Molecular and Anatomical Imaging of Dementia With Lewy Bodies and Frontotemporal Lobar Degeneration. Semin Nucl Med. 2021. PMID: 33402272. doi:10.1053/j.semnuclmed.2020.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。